Kristie L. Kahl

Individuals diagnosed with a high frequency of basal cell carcinomas, a common type of skin cancer, may be at an increased for developing an unrelated cancer, highlighting the need for additional clinical screening.

Recent research showed first-degree relatives of patients with certain types of blood cancers may be at an increased risk for such disease, highlighting the importance of counseling, gene testing and surveillance.

The combination use of Tumor Treating Fields plus paclitaxel more than doubled progression-free survival, with no serious treatment-related side effects in women with recurrent, platinum-resistant ovarian cancer.

In a global analysis, researchers found global lung cancer mortality rates are projected to increase by 43 percent in women; however, breast cancer rates should decline by 9 percent.

Patients who receive anti-PD-1 therapies may experience delayed cutaneous side effects like lesions, eczema or psoriasis, even after treatment has ended.

In this week’s episode of “CURE® Talks Cancer,” we delve into immunotherapy breakthroughs and how a new series of patient summits can help individuals learn more.

Navigating the career space after a cancer diagnosis can be difficult. We spoke to one professional who can help.

The Food and Drug Administration approved Nivestym (filgrastim-aafi), a biosimilar to Neupogen (filgrastim), for five eligible indications.

In this episode of CURE Talks Cancer, we spoke with a patient, survivor, caregiver and two social workers about the benefits of joining a support group and how they can help individuals through a cancer journey.

"Scanxiety" is common in people with cancer, but is particularly prevalent in those with lung cancer, according to a recent survey.

A national survey demonstrated shared feelings across all blood cancer types about treatment options and their side effects, as well as other social, financial and emotional aspects.

The Food and Drug Administration (FDA) granted a priority review to Keytruda (pembrolizumab) for the treatment of previously treated patients with advanced hepatocellular carcinoma (HCC).

In a recent survey, researchers from the University of Colorado Denver found a variety of predictors that affect caregiver burden, and how psychological resilience and future interventions can help.

We spoke with two members of the Moving Mountains for Multiple Myeloma team.

The American Cancer Society issued an updated guideline recommendation that now calls for screening to begin at age 45 for individuals at average risk for colorectal cancer.

Understanding one’s biomarkers, such as microsatellite stable (MSS) or instable (MSI) status in tumors, is key in understanding how a patient with colorectal cancer may be treated.

The Food and Drug Administration (FDA) granted a priority review to Keytruda (pembrolizumab) in combination with chemotherapy as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC), regardless of PD-L1 expression, according to Merck, the manufacturer of the anti-PD-1 agent.

At the GI Cancer Patient Summit, a panel of caregivers drew upon personal experience to offer advice and discuss what more can be done for individuals in this role of the cancer journey.

We spoke with veteran journalist Neil Canavan about his book, A Cure Within: Scientists Unleashing the Immune System to Kill Cancer.

These discussions should include information about the cancer itself, as well as treatment options, side effects, prognosis, and most importantly, the patient’s values.

In the QUADRA study, treatment with Zejula (niraparib) demonstrated durable responses among women with relapsed or refractory ovarian cancer, regardless of BRCA mutation.

According to findings from the ASCO Annual Meeting, insurance disparities still exist, and may even contribute to cancer-specific and comorbidity-associated mortalities in patients with early-stage non-small cell lung cancer.

Phase 2 study results showed that patients with metastatic or unresectable, FGFR-positive bladder cancer may have a third-line option for treatment.

Researchers identified six gene variations that play an important role in the treatment and surveillance of children with medulloblastoma, for which they developed screening and counseling recommendations.

Lynch syndrome – a hereditary condition that increases a person’s risk for developing several types of cancer – is common among people with microsatellite instability-high (MSI-H) tumors, linking it to several new cancer types, according to large genomic study results presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

In this episode of CURE Talks Cancer, we spoke with colorectal cancer survivor Danielle Ripley-Burgess and childhood development specialist Leslie Welch about how parents or caregivers facing a cancer diagnosis can have discussions with children of any age about cancer.

In the Keynote-042 trial, researchers found a four- to eight-month overall survival benefit among patients with non-small cell lung cancer (NSCLC), which was correlated with higher levels of PD-L1 expression, however, further study is warranted.

The application is seeking approval for GARDASIL 9 to be used in women and men aged 27 to 45 years for the prevention of certain cancers and diseases caused by the nine human papillomavirus (HPV) types covered by the vaccine.

In a presentation at the 2018 ASCO Annual Meeting, researchers from Kaiser Permanente also found that women were almost twice as likely to die from the disease compared with non-cancer deaths.

The Food and Drug Administration (FDA) approved Venclexta (venetoclax) in combination with Rituxan (rituximab) for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without the genetic mutation 17p deletion, who have received at least one prior therapy.